On July 2, the British-Swedish pharmaceutical giant AstraZeneca and Kazakhstan’s SK-Pharmacy signed a long-term contract for the establishment of production and technology transfer in Kazakhstan, and the direct supply of original patented medicines manufactured in Kazakhstan by SK Pharmacy.
“Today, SK-Pharmacy and I signed an important agreement that reflects our company’s plans to produce medicines in Kazakhstan,” said Maria Shipuleva, CEO of AstraZeneca in Kazakhstan. “AstraZeneca’s innovative drugs will be produced at the site of a domestic manufacturer, Nobel Almaty Pharmaceutical Factory JSC. In particular, it is planned to contract the production of drugs for the treatment of diabetes mellitus, chronic heart failure, chronic kidney disease, for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma, for the treatment of ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, as well as for the treatment of non-small cell lung cancer. We hope that our activities within the framework of a long-term agreement with SK–Pharmacy will help further develop the country’s healthcare system and, most importantly, improve the quality of life of our Kazakhstani patients.”
Yerzhan Yelekeyev, Chairman of the Management Board of Kazakh Invest, commented that the long-term agreement between AstraZeneca and SK-Pharmacy LLP will provide a positive impetus to implementing an investment project for the contract production of biotechnological drugs in Kazakhstan.
